Endosense launches study of its TactiCath ablation catheter
This article was originally published in Clinica
Executive Summary
Swiss firm Endosense has enrolled the first of 300 patients in the TOCCASTAR clinical study, assessing the TactiCath contact force ablation catheter in the treatment of symptomatic paroxysmal atrial fibrillation (AF). The prospective, randomised, investigational device exemption (IDE) trial is designed to evaluate the effectiveness and safety of TactiCath compared with an approved catheter. Results will be used to support a premarket approval (PMA) application to the US FDA for the TactiCath catheter and accompanying TactiSys system. Geneva-based Endosense launched the catheter outside the US in April 2010; Biotronik is its exclusive distributor in Europe, Latin America, Canada, Africa and the Middle East.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?